PL2558867T3 - Metoda różnicowego określania ilościowego naturalnie przetwarzanych peptydów ograniczonych do HLA w celu opracowania immunoterapii raka, chorób autoimmunologicznych i infekcyjnych - Google Patents
Metoda różnicowego określania ilościowego naturalnie przetwarzanych peptydów ograniczonych do HLA w celu opracowania immunoterapii raka, chorób autoimmunologicznych i infekcyjnychInfo
- Publication number
- PL2558867T3 PL2558867T3 PL11714563T PL11714563T PL2558867T3 PL 2558867 T3 PL2558867 T3 PL 2558867T3 PL 11714563 T PL11714563 T PL 11714563T PL 11714563 T PL11714563 T PL 11714563T PL 2558867 T3 PL2558867 T3 PL 2558867T3
- Authority
- PL
- Poland
- Prior art keywords
- autoimmune
- cancer
- infectious diseases
- restricted peptides
- naturally processed
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 208000035473 Communicable disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32494110P | 2010-04-16 | 2010-04-16 | |
| GBGB1006360.0A GB201006360D0 (en) | 2010-04-16 | 2010-04-16 | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| PCT/EP2011/056056 WO2011128448A1 (en) | 2010-04-16 | 2011-04-15 | Method for differentially quantifying naturally processed hla-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| EP11714563.1A EP2558867B1 (en) | 2010-04-16 | 2011-04-15 | Method for differentially quantifying naturally processed hla-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2558867T3 true PL2558867T3 (pl) | 2018-04-30 |
Family
ID=42245305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11714563T PL2558867T3 (pl) | 2010-04-16 | 2011-04-15 | Metoda różnicowego określania ilościowego naturalnie przetwarzanych peptydów ograniczonych do HLA w celu opracowania immunoterapii raka, chorób autoimmunologicznych i infekcyjnych |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9791444B2 (pl) |
| EP (1) | EP2558867B1 (pl) |
| JP (1) | JP6010019B2 (pl) |
| KR (1) | KR101602010B1 (pl) |
| CN (1) | CN102939540B (pl) |
| AU (1) | AU2011239959B2 (pl) |
| CA (1) | CA2793490C (pl) |
| CY (1) | CY1119861T1 (pl) |
| DK (1) | DK2558867T3 (pl) |
| ES (1) | ES2658268T3 (pl) |
| GB (1) | GB201006360D0 (pl) |
| HR (1) | HRP20180240T1 (pl) |
| HU (1) | HUE036833T2 (pl) |
| IL (1) | IL221860A (pl) |
| LT (1) | LT2558867T (pl) |
| ME (1) | ME03054B (pl) |
| NO (1) | NO2558867T3 (pl) |
| PL (1) | PL2558867T3 (pl) |
| PT (1) | PT2558867T (pl) |
| RS (1) | RS57042B1 (pl) |
| SG (1) | SG183814A1 (pl) |
| SI (1) | SI2558867T1 (pl) |
| TR (1) | TR201802923T4 (pl) |
| WO (1) | WO2011128448A1 (pl) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| WO2013081721A1 (en) * | 2011-11-30 | 2013-06-06 | Battelle Memorial Institute | Biomarkers for lymphoma |
| LT2901341T (lt) | 2012-09-28 | 2019-09-25 | The University Of Connecticut | Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui |
| ES3009756T3 (en) | 2013-08-05 | 2025-03-31 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors, such as lung cancer including nsclc |
| TWI636065B (zh) | 2013-08-05 | 2018-09-21 | 伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| US11338026B2 (en) | 2014-09-10 | 2022-05-24 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
| CN113791220A (zh) * | 2014-09-10 | 2021-12-14 | 豪夫迈·罗氏有限公司 | 免疫原性突变体肽筛选平台 |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| MA49156A (fr) | 2014-12-23 | 2020-03-25 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| LT3388075T (lt) | 2015-03-27 | 2023-11-10 | Immatics Biotechnologies Gmbh | Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003) |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| EA201792501A1 (ru) | 2015-05-13 | 2018-10-31 | Эйдженус Инк. | Вакцины для лечения и профилактики рака |
| IL294183B2 (en) | 2015-05-20 | 2023-10-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| HK1254866A1 (zh) | 2015-06-25 | 2019-07-26 | Immatics Biotechnologies Gmbh | 用於骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物 |
| MA54884A (fr) | 2015-07-01 | 2022-01-12 | Immatics Biotechnologies Gmbh | Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| CR20230563A (es) | 2015-07-06 | 2024-01-22 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-0579) |
| MY189596A (en) * | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| TWI782434B (zh) | 2015-08-28 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 |
| US10335471B2 (en) | 2015-08-28 | 2019-07-02 | Immatics Biotechnologies Gmbh | Method for treating cancer with activated T cells |
| PH12022551111A1 (en) | 2015-10-05 | 2023-08-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| EP3362929B1 (en) * | 2015-10-12 | 2020-08-12 | Nantomics, LLC | Viral neoepitopes and uses thereof |
| MX2018004544A (es) | 2015-10-12 | 2018-11-09 | Nantomics Llc | Composiciones y métodos para los neoepítopos de cáncer viral. |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| MA55153A (fr) | 2016-02-19 | 2021-09-29 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| IL302705A (en) | 2016-03-01 | 2023-07-01 | Immatics Biotechnologies Gmbh | Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| CN109071605A (zh) | 2016-04-06 | 2018-12-21 | 伊玛提克斯生物技术有限公司 | 用于aml和其他癌症免疫治疗的新型肽和肽组合物 |
| AU2017254477A1 (en) * | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| TWI796299B (zh) | 2016-08-26 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| SI3573647T1 (sl) | 2017-01-27 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka |
| WO2018138257A1 (en) | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| US10738100B2 (en) | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Biontech Us Inc. | Protein antigens and uses thereof |
| EA201992416A1 (ru) | 2017-04-10 | 2020-02-25 | Имматикс Байотекнолоджиз Гмбх | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака |
| WO2018189148A1 (en) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
| BR112019020959A2 (pt) | 2017-04-10 | 2020-05-05 | Immatics Biotechnologies Gmbh | peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| MX2019015879A (es) | 2017-07-07 | 2020-02-07 | Immatics Biotechnologies Gmbh | Nuevos peptidos y nuevas combinacones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluyendo el nsclc, el sclc y otros canceres. |
| US10800823B2 (en) | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
| TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| MX2020014243A (es) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| CN109002689B (zh) * | 2018-07-23 | 2020-10-09 | 西安交通大学医学院第一附属医院 | T细胞数据处理方法及装置 |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| DE102018122546B3 (de) | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| TW202028224A (zh) | 2018-09-17 | 2020-08-01 | 德商英麥提克生物技術股份有限公司 | B*44限制肽在抗癌免疫治療的用途和相關方法 |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| WO2020245839A1 (en) * | 2019-06-06 | 2020-12-10 | Dr. Reddy's Laboratories Limited | Method for identification and absolute quantification of product-related impurities in a protein using high-resolution mass spectrometry |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| JP2022543687A (ja) | 2019-08-09 | 2022-10-13 | イマティクス ユーエス，アイエヌシー． | ペプチド質量分析断片化を予測するための方法 |
| US12480958B2 (en) | 2019-08-13 | 2025-11-25 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:MHC binding polypeptides |
| IL269564B2 (en) | 2019-09-23 | 2023-11-01 | Keter Home & Garden Products Ltd | Sawhorse |
| US11920202B2 (en) | 2020-04-09 | 2024-03-05 | University Of Connecticut | Unbiased identification of tumor rejection mediating neoepitopes |
| CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| TW202229312A (zh) | 2020-09-29 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物 |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11161892B1 (en) | 2020-12-07 | 2021-11-02 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的ｈｌａ展示肽 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| PE20240779A1 (es) | 2021-07-27 | 2024-04-17 | Immatics Biotechnologies Gmbh | Proteinas de union a antigenos que se unen especificamente a ct45 |
| US12531162B1 (en) * | 2023-05-31 | 2026-01-20 | Northeastern University | Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net |
| WO2025021979A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| CN121358777A (zh) | 2023-07-27 | 2026-01-16 | 伊玛提克斯生物技术有限公司 | 抗mageb2的抗原结合蛋白 |
| WO2025040598A2 (en) | 2023-08-18 | 2025-02-27 | Immatics Biotechnologies Gmbh | Peptides displayed by mhc for use in immunotherapy against different types of cancer |
| US12562256B2 (en) * | 2023-11-07 | 2026-02-24 | New York University | Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy |
| WO2025125535A1 (en) * | 2023-12-13 | 2025-06-19 | Immatics Biotechnologies Gmbh | Differential population-scale immunopeptidomics |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| WO2025233432A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide |
| WO2026008886A1 (en) | 2024-07-05 | 2026-01-08 | Immatics Biotechnologies Gmbh | Means and methods for the quantification of target expression |
| WO2026033136A1 (en) | 2024-08-09 | 2026-02-12 | Immatics Biotechnologies Gmbh | Advanced treatment modalities for anti-prame tcr-engineered immune cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1425586E (pt) | 2001-09-14 | 2007-12-31 | Electrophoretics Ltd | Marcadores de massa |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| WO2005076009A2 (en) | 2004-01-28 | 2005-08-18 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumour-associated peptides |
| EP1760089B1 (en) * | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| GB0611669D0 (en) * | 2006-06-13 | 2006-07-19 | Astrazeneca Uk Ltd | Mass spectrometry biomarker assay |
| EP2113253B1 (en) | 2008-04-30 | 2010-03-31 | Immatics Biotechnologies GmbH | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines |
-
2010
- 2010-04-16 GB GBGB1006360.0A patent/GB201006360D0/en not_active Ceased
-
2011
- 2011-02-10 ME MEP-2018-25A patent/ME03054B/me unknown
- 2011-04-15 SI SI201131436T patent/SI2558867T1/en unknown
- 2011-04-15 EP EP11714563.1A patent/EP2558867B1/en active Active
- 2011-04-15 PL PL11714563T patent/PL2558867T3/pl unknown
- 2011-04-15 HU HUE11714563A patent/HUE036833T2/hu unknown
- 2011-04-15 CN CN201180018775.6A patent/CN102939540B/zh not_active Expired - Fee Related
- 2011-04-15 DK DK11714563.1T patent/DK2558867T3/da active
- 2011-04-15 HR HRP20180240TT patent/HRP20180240T1/hr unknown
- 2011-04-15 CA CA2793490A patent/CA2793490C/en active Active
- 2011-04-15 LT LTEP11714563.1T patent/LT2558867T/lt unknown
- 2011-04-15 US US13/640,989 patent/US9791444B2/en active Active
- 2011-04-15 ES ES11714563.1T patent/ES2658268T3/es active Active
- 2011-04-15 NO NO11714563A patent/NO2558867T3/no unknown
- 2011-04-15 WO PCT/EP2011/056056 patent/WO2011128448A1/en not_active Ceased
- 2011-04-15 TR TR2018/02923T patent/TR201802923T4/tr unknown
- 2011-04-15 US US13/087,948 patent/US9791443B2/en active Active
- 2011-04-15 RS RS20180138A patent/RS57042B1/sr unknown
- 2011-04-15 AU AU2011239959A patent/AU2011239959B2/en not_active Ceased
- 2011-04-15 KR KR1020127029919A patent/KR101602010B1/ko not_active Expired - Fee Related
- 2011-04-15 PT PT117145631T patent/PT2558867T/pt unknown
- 2011-04-15 SG SG2012063137A patent/SG183814A1/en unknown
- 2011-04-15 JP JP2013504295A patent/JP6010019B2/ja active Active
-
2012
- 2012-09-05 IL IL221860A patent/IL221860A/en active IP Right Grant
-
2018
- 2018-01-30 CY CY20181100108T patent/CY1119861T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130095186A (ko) | 2013-08-27 |
| JP6010019B2 (ja) | 2016-10-19 |
| SI2558867T1 (en) | 2018-04-30 |
| IL221860A (en) | 2017-09-28 |
| US20130096016A1 (en) | 2013-04-18 |
| CY1119861T1 (el) | 2018-06-27 |
| GB201006360D0 (en) | 2010-06-02 |
| AU2011239959B2 (en) | 2015-04-16 |
| KR101602010B1 (ko) | 2016-03-09 |
| US9791443B2 (en) | 2017-10-17 |
| HUE036833T2 (hu) | 2018-08-28 |
| ME03054B (me) | 2018-10-20 |
| EP2558867A1 (en) | 2013-02-20 |
| HRP20180240T1 (hr) | 2018-03-09 |
| NO2558867T3 (pl) | 2018-05-05 |
| AU2011239959A1 (en) | 2012-08-09 |
| PT2558867T (pt) | 2018-02-08 |
| CA2793490C (en) | 2017-09-12 |
| ES2658268T3 (es) | 2018-03-09 |
| SG183814A1 (en) | 2012-11-29 |
| US20110257890A1 (en) | 2011-10-20 |
| RS57042B1 (sr) | 2018-05-31 |
| DK2558867T3 (da) | 2018-01-29 |
| WO2011128448A1 (en) | 2011-10-20 |
| CA2793490A1 (en) | 2011-10-20 |
| TR201802923T4 (tr) | 2018-03-21 |
| CN102939540B (zh) | 2014-12-17 |
| US9791444B2 (en) | 2017-10-17 |
| CN102939540A (zh) | 2013-02-20 |
| EP2558867B1 (en) | 2017-12-06 |
| LT2558867T (lt) | 2018-02-12 |
| JP2013525759A (ja) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL221860A (en) | Natural Differential Quantification Method for Limited Amino Acids for Cancer, Infectious and Immune Diseases and Treatment | |
| ZA201306646B (en) | Hla-restricted, peptide-specific antigen binding proteins | |
| EP2646283A4 (en) | Loading analysis system and method | |
| EP2534267A4 (en) | DIGITAL ANALYSIS ANALYZES | |
| EP2732363A4 (en) | SUBMENUS FOR CONTEXTUAL MENUS SYSTEM | |
| IL249501B (en) | A process for creating antibodies | |
| PL2628527T3 (pl) | Układ do przetwarzania rtęci w gazach spalinowych | |
| IL217100A0 (en) | System for gas processing | |
| EP2533191A4 (en) | IMAGE PROCESSING SYSTEM, IMAGE PROCESSING METHOD, AND PROGRAM THEREOF | |
| PL2646466T3 (pl) | Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie | |
| PL2481818T3 (pl) | Sposób wykrywania wirusa brodawczaka ludzkiego oparty na sekwencjonowaniu metodą Solexa | |
| EP2620759A4 (en) | Exhaust gas analysis system and exhaust gas analysis program | |
| GB2509682B (en) | Biomarkers useful for detection of types, grades and stages of human breast cancer | |
| GB2485257B (en) | System and method for curating mass spectral libraries | |
| IL217276A (en) | Phosphorilization plasma hsp90α polypeptide, antibodies against it and their use in cancer diagnosis | |
| EP2538708A4 (en) | METHOD AND SYSTEM FOR PROCESSING ADDED VALUE SERVICES | |
| GB201019635D0 (en) | System and method for baggage reclaim | |
| EP2582199A4 (en) | M2M SYSTEM AND METHOD OF PROCESSING SERVICES THEREOF | |
| ZA201302123B (en) | Raw gas collection system | |
| EP2557533A4 (en) | SPECIFICATION DETERMINATION SYSTEM, SPECIFICATION DETERMINATION METHOD, AND SPECIFICATION DETERMINATION PROGRAM | |
| GB201214138D0 (en) | Gas compression and gas upgrade system | |
| AU2011905412A0 (en) | Imaging Spectroscopy Processing Pipeline and File Format | |
| IL231507A0 (en) | Antibodies directed against marker peptides, methods and uses | |
| GB201020874D0 (en) | Tyre processing method | |
| GB201015013D0 (en) | Refuse processing apparatus & vehicle |